Eagle Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Eagle Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-293,614	Closed	-$13.8M	–	685
2019 Q4	$13.8M	Sell	293,614 -712,270	-71%	-$31.5M	0.07%	268
2019 Q3	$23.8M	Buy	1,005,884 +390,415	+63%	+$11.6M	0.12%	218
2019 Q2	$18.5M	Buy	+615,469	New	+$14.1M	0.09%	237

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Asset Management's RARX Position: Q1 2020 in Review

Eagle Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 293,614 shares — an estimated $13.8M sold.

Eagle Asset Management first reported a position in RARX in Q2 2019 and held it in 3 quarters. The position peaked at $23.8M in Q3 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

Eagle Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Eagle Asset Management sold 293,614 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $13.8M.
Eagle Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
Eagle Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $23.8M in Q3 2019.
144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Eagle Asset Management's 13F filing for Q1 2020, filed 11 May 2020.